{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:40:03Z","timestamp":1776318003173,"version":"3.50.1"},"reference-count":33,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.6941","type":"journal-article","created":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T22:15:14Z","timestamp":1475273714000},"page":"2777-2783","source":"Crossref","is-referenced-by-count":8,"title":["Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis"],"prefix":"10.2169","volume":"55","author":[{"given":"Takeshi","family":"Kuroda","sequence":"first","affiliation":[{"name":"Niigata University Health Administration Center, Japan"},{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohito","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Health and Nutrition, Faculty of Human Life Studies, University of Niigata Prefecture, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Nozawa","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroe","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Nakatsue","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Wada","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nagaoka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 70: 246-256, 1991.","DOI":"10.1097\/00005792-199107000-00002"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Gillmore JD, Lovat L, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid protein. Lancet 358: 24-29, 2001.","DOI":"10.1016\/S0140-6736(00)05252-1"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Husby G, Marhaug F, Dowton B, Sletten K, Sipe JD. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid 1: 119-137, 1994.","DOI":"10.3109\/13506129409148635"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Cunnane G, Whitehead AS. Amyloid precursors and amyloidosis in rheumatoid arthritis. Baillieres Clin Rheumatol 13: 615-628, 1999.","DOI":"10.1053\/berh.1999.0049"},{"key":"5","unstructured":"5. Kobayashi H, Tada S, Fuchigami T, et al. Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. Br J Rheumatol 35: 44-49, 1996."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. El Mansoury TM, Hazenberg BP, El Badawy SA, et al. Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics. Ann Rheum Dis 61: 42-47, 2002.","DOI":"10.1136\/ard.61.1.42"},{"key":"7","unstructured":"7. Wakhlu A, Krisnani N, Hissaria P, Aggarwal A, Misra R. Prevalence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis. J Rheumatol 30: 948-951, 2003."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Husby G. Amyloidosis and rheumatoid arthritis. Clin Exp Rheumatol 3: 173-180, 1985.","DOI":"10.1007\/BF02030751"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kuroda T, Tanabe N, Sakatsume M, et al. Comparison of gastroduodenal, renal and abdominal fat biopsies for diagnosing amyloidosis in rheumatoid arthritis. Clin Rheumatol 21: 123-128, 2002.","DOI":"10.1007\/PL00011217"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Carmona L, Gonzalez-Alvaro I, Balsa A, Angel Belmonte M, Tena X, Sanmarti R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 62: 897-900, 2003.","DOI":"10.1136\/ard.62.9.897"},{"key":"11","unstructured":"11. Misra R, Wakhlu A, Krishnani N, Hissaria P, Aggarwal A. Prevalence of silent amyloidosis in rheumatoid arthritis and its clinical significance. J Rheumatol 31: 1031-1034, 2004."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lipsky PE, van der Heijde DM, St Clair EW, et al. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group: infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Eng J Med 343: 1594-1562, 2000.","DOI":"10.1056\/NEJM200011303432202"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI) evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66: 1162-1167, 2007.","DOI":"10.1136\/ard.2006.068064"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow-up report of tolerability and efficacy. Arthritis Rheum 48: 2019-2024, 2003.","DOI":"10.1002\/art.11163"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizmab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthrits Rheum 54: 2997-3000, 2006.","DOI":"10.1002\/art.22118"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kuroda T, Otaki Y, Sato H, et al. A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab. Rheumatol Int 28: 1155-1159, 2008.","DOI":"10.1007\/s00296-008-0590-z"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kuroda T, Wada Y, Kobayashi D, et al. Effective anti-TNF-\u03b1 therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. J Rheumatol 36: 2409-2415, 2009.","DOI":"10.3899\/jrheum.090101"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kuroda T, Tanabe N, Kobayashi D, et al. Treatment with biologic agents improves the prognosis of patients with rheumatoid arthritis and amyloidosis. J Rheumatol 39: 1348-1354, 2012.","DOI":"10.3899\/jrheum.111453"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324, 1988.","DOI":"10.1002\/art.1780310302"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kuroda T, Tanabe N, Kobayashi D, et al. Programmed initiation of hemodialysis for systemic amyloidosis patients associated with rheumatoid arthritis. Rheumatol Int 31: 1177-1182, 2011.","DOI":"10.1007\/s00296-010-1448-8"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Miyasaka N, Takeuchi T, Eguchi K. Proposed [corrected] Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol 15: 4-8, 2005.","DOI":"10.3109\/s10165-004-0357-7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Salaffi F, Peroni M, Ferraccioli GF. Discriminating ability of composite indices for measuring disease activity in rheumatoid arthritis: a comparison of the Chronic Arthritis Systemic Index, Disease Activity Score and Thompson&apos;s articular index. Rheumatology (Oxford) 39: 90-96, 2000.","DOI":"10.1093\/rheumatology\/39.1.90"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kobayashi H, Tada S, Fuchigami T, et al. Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. Br J Rheumatol 35: 44-49, 1996.","DOI":"10.1093\/rheumatology\/35.1.44"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69: 325-331, 2010.","DOI":"10.1136\/ard.2009.113696"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sato H, Sakai T, Sugaya T, et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 28: 1113-1116, 2009.","DOI":"10.1007\/s10067-009-1185-0"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lunt M, Watson KD, Dixon WG, Symmons DP, Hyrich KL; The BSRBR Control Centre Consortium; on behalf of the BSR Biologics Register. No evidence of association between anti-TNF treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 62: 3145-3153, 2010.","DOI":"10.1002\/art.27660"},{"key":"27","unstructured":"27. Dixon WG, Hyrich KL, Watson KD, Lunt M; BSRBR Control Centre Consortium, Symmons DP; British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 69: 1180-1191, 2010."},{"key":"28","unstructured":"28. Sakka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 26: S35-S61, 2008."},{"key":"29","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","volume":"359","author":"HK Dhoi","year":"2002","unstructured":"29. Dhoi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359: 1173-1177, 2002.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kuroda T, Tanabe N, Sato H, et al. Outcome of patients with reactive amyloidosis associated with rheumatoid arthritis in dialysis treatment. Rheumatol Int 26: 1147-1153, 2006.","DOI":"10.1007\/s00296-006-0204-6"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kuroda T, Tanabe T, Harada T, et al. Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 25: 498-505, 2006.","DOI":"10.1007\/s10067-005-0079-z"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 3: 1526-1533, 2008.","DOI":"10.2215\/CJN.00950208"},{"key":"33","unstructured":"33. Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol 25: 518-522, 2007."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/19\/55_55.6941\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T05:05:06Z","timestamp":1568437506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/19\/55_55.6941\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":33,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.6941","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}